scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Mark J Ratain | Q87725760 |
P2093 | author name string | Federico Innocenti | |
P433 | issue | 5 Suppl 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | irinotecan | Q412197 |
P304 | page(s) | 52-5 | |
P577 | publication date | 2003-05-01 | |
P1433 | published in | Oncology | Q1998293 |
P1476 | title | Irinotecan treatment in cancer patients with UGT1A1 polymorphisms | |
P478 | volume | 17 |
Q37345974 | Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review |
Q26741009 | Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives |
Q43284467 | Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs? |
Q38260248 | Gene replacement therapy for genetic hepatocellular jaundice |
Q28295988 | Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome) |
Q36775605 | Impact of pharmacogenomics on clinical practice in oncology |
Q28287024 | Irinotecan pharmacogenomics |
Q39354491 | Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition. |
Q36190895 | Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies |
Search more.